Heikki Lanckriet Acquires 3,000 Shares of 4basebio (LON:4BB) Stock

4basebio PLC (LON:4BB) insider Heikki Lanckriet acquired 3,000 shares of the company’s stock in a transaction on Tuesday, February 10th. The shares were acquired at an average price of GBX 576 per share, for a total transaction of £17,280.

4basebio Stock Performance

4basebio stock opened at GBX 584.45 on Friday. 4basebio PLC has a 52 week low of GBX 520 and a 52 week high of GBX 1,220. The company has a current ratio of 2.73, a quick ratio of 3.52 and a debt-to-equity ratio of 201.47. The stock has a market cap of £90.50 million, a P/E ratio of -5.90 and a beta of 1.09. The stock has a 50 day moving average of GBX 603.43 and a 200-day moving average of GBX 736.74.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.